logo
logo
Sign in

Monoclonal Antibody Therapeutics Market To Reach US$ 205,385.6 Million By 2023

avatar
Ashish Thapa
Monoclonal Antibody Therapeutics Market To Reach US$ 205,385.6 Million By 2023

Market Overview:

Monoclonal antibody therapeutics are highly effective in targeting specific proteins in the body and have gained immense popularity due to their advantages such as high specificity, low toxicity, and reduced side effects. The increasing prevalence of chronic diseases, rising geriatric population, and advancements in biotechnology are driving the demand for these therapeutics. Furthermore, the need to develop targeted therapies for diseases such as cancer, autoimmune disorders, and infectious diseases is also contributing to market growth.


Market Key Trends:

One key trend in the monoclonal antibody therapeutics market is the growing adoption of personalized medicine. With advancements in genomic technology, it has become possible to tailor treatment plans according to an individual's genetic makeup. This approach allows for more accurate diagnosis, prognosis, and treatment selection, leading to improved patient outcomes. Personalized medicine also enables the development of targeted monoclonal antibody therapeutics that specifically address the molecular characteristics of a patient's disease. This trend is gaining traction as it offers a more precise and effective approach to healthcare, leading to increased demand for monoclonal antibody therapeutics.

The global Monoclonal Antibody Therapeutics Market is estimated to be valued at US$205,385.6 Million in 2023 and is expected to exhibit a CAGR of 12.69% over the forecast period from 2023 to 2030, according to a report published by Coherent Market Insights.


Segment Analysis:


The monoclonal antibody therapeutics market can be segmented based on type, application, and end user.


In terms of type, the dominating sub-segment is fully human antibodies. Fully human antibodies are derived from the human immune system and have a lower risk of adverse reactions compared to other types of antibodies, such as chimeric or humanized antibodies. These antibodies are highly specific, providing targeted therapy with minimal side effects. Due to their effectiveness and safety profile, fully human antibodies are highly preferred by healthcare professionals and patients, leading to their dominance in the market.


Key Takeaways:


The global monoclonal antibody therapeutics market is expected to witness high growth, exhibiting a CAGR of 12.69% over the forecast period of 2023-2030. This growth can be attributed to several factors. Firstly, the increasing prevalence of chronic diseases, such as cancer, autoimmune disorders, and infectious diseases, is driving the demand for monoclonal antibody therapeutics. These therapeutics offer targeted treatment options, reducing the toxicity associated with traditional chemotherapy or immunosuppressive drugs.


Regionally, North America is the fastest-growing and dominating region in the market. This can be attributed to the presence of well-established pharmaceutical companies, advancements in biotechnology research, and favorable reimbursement policies. Additionally, the high prevalence of chronic diseases in the region has increased the demand for innovative treatment options like monoclonal antibody therapeutics.


Key players operating in the monoclonal antibody therapeutics market are Pfizer Inc., Novartis AG, Bayer AG, Sanofi, F. Hoffmann-La Roche Ltd, Eli Lilly and Company, Merck KGaA, GSK plc., AbbVie Inc., Bristol-Myers Squibb Company, Regeneron Pharmaceuticals Inc., AstraZeneca, AbCellera Biologics Inc., Molecular Depot LLC, DAIICHI SANKYO COMPANY, LIMITED., Abbott, Biogen, Thermo Fisher Scientific, Inc., Cell Signaling Technology, Inc, Intas Pharmaceuticals Ltd., Avantor Inc., UCB S.A., Merus N.V., GENEXTGENOMICS.COM, and Biogenuix. These key players have a strong presence in the market and are focused on research and development activities to introduce new and improved monoclonal antibody therapeutics.

Read More: https://www.rapidwebwire.com/monoclonal-antibody-therapeutics-market-growing-demand-size-and-share-analysis/

 

collect
0
avatar
Ashish Thapa
guide
Zupyak is the world’s largest content marketing community, with over 400 000 members and 3 million articles. Explore and get your content discovered.
Read more